247257-48-3 Usage
Description
2-Butyl-5-dimethylaminothiocarbonylmethyl-6-methyl-3-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]pyrimidin-4(3H)-one is a complex organic compound with a unique molecular structure. It is characterized by its long and intricate chemical name, which reflects the various functional groups and structural elements that make up the molecule. 2-Butyl-5-dimethylaminothiocarbonylmethyl-6-methyl-3-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]pyrimidin-4(3H)-one may have potential applications in various fields, such as pharmaceuticals, materials science, or chemical research, due to its specific properties and reactivity.
Uses
Used in Pharmaceutical Industry:
2-Butyl-5-dimethylaminothiocarbonylmethyl-6-methyl-3-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]pyrimidin-4(3H)-one is used as a potential therapeutic agent for various medical conditions. Its unique molecular structure may allow it to interact with specific biological targets, such as receptors or enzymes, which could make it a valuable tool in the development of new drugs.
Used in Chemical Research:
2-Butyl-5-dimethylaminothiocarbonylmethyl-6-methyl-3-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]pyrimidin-4(3H)-one can also be used as a research tool in the field of chemistry, particularly in the study of reaction mechanisms, synthetic methodologies, and the development of new chemical processes. Its complex structure and various functional groups may provide insights into new reaction pathways and help researchers understand the behavior of similar compounds.
Used in Materials Science:
2-Butyl-5-dimethylaminothiocarbonylmethyl-6-methyl-3-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]pyrimidin-4(3H)-one may have potential applications in the development of new materials, such as polymers, coatings, or advanced materials with specific properties. Its unique structure and reactivity could be harnessed to create novel materials with improved performance characteristics.
Biological Activity
Fimasartan (Kanarb) is a non-peptide angiotensin II receptor antagonist (ARB) with noncompetitive, insurmountable binding with the AT1 receptor. It is used for the treatment of hypertension and heart failure.
Mechanism of action
Angiotensin II activates AR1 leading to vasoconstriction and increased noradrenaline release which further increases vasoconstriction via action at α1-adrenergic receptors. It also stimulates secretion of aldosterone which acts to increase sodium and water reabsorption in the renal tubules. Fimasartan bind to and antagonizes AR1 preventing vasoconstriction and reducing aldosterone secretion to increase natriuresis leading to a reduction in blood volume. Together these effects produce an anti-hypertensive effect.
Check Digit Verification of cas no
The CAS Registry Mumber 247257-48-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,4,7,2,5 and 7 respectively; the second part has 2 digits, 4 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 247257-48:
(8*2)+(7*4)+(6*7)+(5*2)+(4*5)+(3*7)+(2*4)+(1*8)=153
153 % 10 = 3
So 247257-48-3 is a valid CAS Registry Number.
247257-48-3Relevant articles and documents
Process for Preparation of Fimasartan and Intermediate for Preparing the Same
-
, (2020/10/20)
The present invention relates to a simple and economically process for preparing fimasartan and its preparation intermediates. (by machine translation)
Method for preparing Fimasartan
-
, (2019/01/16)
The invention discloses a method for preparing Fimasartan. The method comprises the steps that valeronitrile is used as a raw material to prepare pentanimidamide hydrochloride, then pentanimidamide hydrochloride and acetylsuccinic acid diethyl ester conduct a cyclization reaction and an amidation reaction to prepare 2-(2-normal-butyl-4-hydroxyl-6-methylpyrimidine-5-radical)-N,N-dimethylacetamide (intermediate II), the intermediate II is subjected to sulfo-carbonylation through a Lawesson's reagent to obtain 2-(2-normal-butyl-4-hydroxyl-6-methylpyrimidine-5-radical)-N,N-dimethylacetamide (intermediate III), the intermediate III is subjected to an N-alkylation reaction, radicals are protected through detritylation, and Fimasartan is prepared. The preparation method has the advantages of highreaction selectivity, high synthesis yield, high reaction efficiency and the like.
Pyrimidinone compounds, pharmaceutical compositions containing the compounds and the process for preparing the same
-
, (2008/06/13)
The present invention relates to a novel pyrimidinone compounds and the pharmaceutical acceptable salts thereof having remarkable antagonistic action against angiotensin II receptor, thereby, being useful in treating cardiovascular disease caused by binding angiotensin II to its receptor.